|Titre :||Cannabidiol (CBD): Critical review report|
|Auteurs :||OMS / WHO ; Expert Committee on Drug Dependence, Fortieth Meeting (4-7 June 2018; Geneva)|
|Type de document :||Rapport|
|Editeur :||Genève : OMS / WHO, 2018|
|Format :||28 p.|
|Discipline :||PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)|
Thésaurus TOXIBASECANNABINOIDES ; USAGE THERAPEUTIQUE ; CHIMIE ; PHARMACOLOGIE ; EFFET SECONDAIRE ; POTENTIEL ADDICTIF ; ABUS ; CONTROLE DES STUPEFIANTS
Cannabidiol (CBD) is one of the naturally occurring cannabinoids found in cannabis plants. It is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a cannabidiolic acid precursor, although it can also be produced synthetically.
In experimental models of abuse liability, CBD appears to have little effect on conditioned place preference or intracranial self-stimulation. In an animal drug discrimination model CBD failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or dependence potential.
CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with one pure CBD product (Epidiolex®) with completed Phase III trials and under current review for approval in the U.S. There is also preliminary evidence that CBD may be a useful treatment for a number of other medical conditions.
There is unsanctioned medical use of CBD based products with oils, supplements, gums, and high concentration extracts available online for the treatment of many ailments.
CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as a result of drug-drug interactions between CBD and patients' existing medications.
Several countries have modified their national controls to accommodate CBD as a medicinal product.
To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD.
|Domaine :||Autres substances / Other substances ; Drogues illicites / Illicit drugs|
|Sous-type de document :||Revue de la littérature / Literature review|
|Refs biblio. :||100|
|URL :||Cannabidiol - Questions-réponses (Décembre 2017)|